We are live on ! Find out more
TA

Tamarack Advisers Portfolio holdings

AUM $2.12M
1-Year Est. Return 58.09%
This Fund
S&P 500
This Quarter Est. Return
+6.4%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$211M
AUM Growth
-$31.9M
Cap. Flow
-$34.9M
Cap. Flow %
-16.5%
Top 10 Hldgs %
55.13%
Holding
62
New
14
Increased
11
Reduced
20
Closed
16

Top Buys

Rank Stock Value
1
CI icon
Cigna
CI
+$15.7M
2
MRK icon
Merck
MRK
+$6.7M
3
GILD icon
Gilead Sciences
GILD
+$4.79M
4
EXEL icon
Exelixis
EXEL
+$3.91M
5
INMD icon
InMode
INMD
+$3.81M

Top Sells

Rank Stock Value
1
THC icon
Tenet Healthcare
THC
+$10.3M
2
HUM icon
Humana
HUM
+$9.28M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$7.95M
4
STRM
Streamline Health Solutions
STRM
+$7.35M
5
CALY
Callaway Golf Company
CALY
+$5.49M

Sector Composition

Rank Sector Weight
1 Healthcare 90.32%
2 Consumer Staples 3.22%
3 Technology 0.69%
4 Consumer Discretionary 0%
5 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRGO icon
51
Perrigo
PRGO
$1.4B
– –
-10,000
Closed -$389K
RIGL icon
52
CALL
Rigel Pharmaceuticals
RIGL
$681M
– –
-571
Closed -$14K
SMG icon
53
ScottsMiracle-Gro
SMG
$3.82B
– –
-30,000
Closed -$4.83M
STRM
54
DELISTED
Streamline Health Solutions
STRM
– –
-328,725
Closed -$7.35M
TDOC icon
55
PUT
Teladoc Health
TDOC
$1.22B
– –
-250
Closed -$584K
UTHR icon
56
United Therapeutics
UTHR
$25.8B
– –
-15,000
Closed -$3.24M
XBI icon
57
State Street SPDR S&P Biotech ETF
XBI
$9.95B
– –
-25,000
Closed -$2.8M
SLGCW
58
DELISTED
SomaLogic, Inc. Warrant
SLGCW
– –
-20,000
Closed -$67K
1 2
3

Similar funds

SCM
SevenOneSeven Capital Management Lancaster, Pennsylvania $2.17M AUM 8.67% 1-Year Est. Return
LBC
Lawrence B. Cohen $2.06M AUM 34.47% 1-Year Est. Return
ICM
ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return
LCMP
Linse Capital Management PR San Juan, Puerto Rico $2.31M AUM
GIP
General Industrial Partners London, United Kingdom $2.57M AUM
STC
Sarah T. Connolly $1.11M AUM 24.13% 1-Year Est. Return
GC
Gilfoyle & Co San Francisco, California $671K AUM
DU
Delphia (USA) Toronto, Ontario, Canada $445K AUM 28.82% 1-Year Est. Return

Tamarack Advisers's Q1 2022 Portfolio in Review

As of Q1 2022, Tamarack Advisers held 62 positions worth $211M, down 13% from $243M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Tamarack Advisers withdrew a net $34.9M in Q1 2022, closing 16 positions and reducing 20 holdings. Its most notable exit was Humana, an estimated $9.28M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 84% a quarter earlier, followed by Consumer Staples and Technology.

Against the trend, Tamarack Advisers opened a new position in Gilead Sciences worth $4.46M.

  • Tamarack Advisers's largest Q1 2022 buy was Gilead Sciences: 75,000 shares worth $4.46M.
  • Tamarack Advisers added most to Cigna in Q1 2022, an estimated $15.7M increase.
  • Tamarack Advisers's biggest Q1 2022 reduction was Tenet Healthcare, cutting an estimated $10.3M.
  • Tamarack Advisers fully exited Humana in Q1 2022, selling an estimated $9.28M.
  • Tamarack Advisers's ten largest holdings make up 55% of its $211M portfolio in Q1 2022.
  • Tamarack Advisers opened 14 new positions and closed 16 in Q1 2022.
  • Tamarack Advisers's portfolio value fell 13% quarter-over-quarter to $211M.

Based on Tamarack Advisers's 13F filing for Q1 2022, filed 11 May 2022.